| |
Eastern Biotech
collaborates with Fulgent
Diagnostics (USA) to launch
new genetic panel to
identify inherited cancer
(Dubai, UAE) --
The Comprehensive Cancer
Panel is a new product that
analyzes 122 genes
associated with the most
common hereditary cancer
syndromes that involve
diverse cancers including
breast, colorectal,
endometrial, fanconi anemia,
gastric, hematologic
malignancy, melanoma,
nervous system/brain,
ovarian, pancreatic,
paraganglioma-pheochromocytoma,
prostate, renal/urinary,
sarcoma, and thyroid.
"Next
Generation Sequencing (NGS)
is one of the most important
technological advancements
in genetic sequencing in the
recent years. Eastern
Biotech has ensured to
choose the right set of
genetic tests that
incorporate this new
technology, for its clients
in the Middle East” says Dr
Amrish Kamboj, Chief
Operating Officer/Specialist
Pathologist, Eastern Biotech
& Life Sciences.
Additionally, Dr. Kamboj
explains that the reason
most individuals develop
cancer later in life is due
to the fact that the
cancer-causing genes mutate
or change over a period of
time. However, some are born
with a gene mutation,
inherited from either
parent, that predisposes
them to cancer. Cancer
caused by an inherited gene
mutation is known as
"hereditary cancer”.
Dr.
Alexandra Obregon, Certified
Genetic Counselor,
International Outreach
Program Manager at Fulgent
Diagnostics, says “Early
onset cancer, multiple
primary cancers in the same
individual, or a clear
excess of certain types of
cancer are suggestive of
hereditary syndromes.
Identifying the mutation
that causes the hereditary
cancer syndrome in a family
allows the implementation of
risk reducing protocols
which improve the outcomes
for these patients ”.
"We are
excited to collaborate with
Eastern Biotech in their
efforts to facilitate
genetic testing in the
Middle East. We are
confident that their
leadership will facilitate
access of Middle Eastern
populations to genetic
services that are showing
impact in cancer prevention
in other places of the
world.” added Dr. Obregon.
According to
Eastern Biotech, inherited
genetic mutations can
escalate a person’s risk of
developing cancer. While
average women have a 12%
risk of developing breast
cancer, people with a
mutation that predispose
them to breast cancer might
have a risk above 90%;
similarly, predisposition to
colorectal cancer increases
the base risk of 5 to 6 % to
50-100%. Once the mutation
that causes hereditary
cancer in a family is
identified, it is possible
to identify other family
members at risk, even before
they develop cancer,
enabling primary cancer
prevention. Risk reducing
strategies are showing
success lowering the
incidence and impact of
cancer in families with
genetic risk.
Founded in 2005, Eastern
Biotech & Life Sciences is a
biotechnology company
headquartered in Dubai,
United Arab Emirates.
To learn more about Eastern
Biotech & Life Sciences
visit:
www.easternbiotech.com
PRINT
THIS ARTICLE
|
